← Back to all trials
Completed
NCT00148837
Efficacy of Prazosin Versus Placebo Associated With Peg-interferon Alpha 2b and Ribavirin in Chronic Hepatitis C With Genotype 1 or 4 and Severe Fibrosis
Conditions: Hepatitis C, Chronic, Fibrosis
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: PHASE2
Enrollment: 112
Sponsor: French National Agency for Research on AIDS and Viral Hepatitis
Location: Hopital du haut Leveque Pessac
Summary
Viral hepatitis C prognosis is related to the presence of a fibrosis and to the risk of developing cirrhosis or hepatic cancer. The study will evaluate the efficacy of prazosin to make hepatic fibrosis regress, in patients with chronic hepatitis C and severe fibrosis.
Eligibility Criteria
Inclusion Criteria:
* Chronic viral hepatitis C, genotype 1 or 4
* Fibrosis F3 or F3-F4, assessed by the scoring Metavir system
* Initial treatment against HCV
Exclusion Criteria:
* Psychiatric pathology
* Alcool consummation
* Pregnancy or plan of pregnancy
* Breastfeeding
Source: ClinicalTrials.gov (NCT00148837). StuddyBuddy aggregates publicly available trial information.
